BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23100309)

  • 1. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience.
    Itonaga H; Tsushima H; Taguchi J; Fukushima T; Taniguchi H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; Onimaru Y; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Uike N; Miyazaki Y
    Blood; 2013 Jan; 121(1):219-25. PubMed ID: 23100309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
    Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
    Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.
    Yonekura K; Utsunomiya A; Takatsuka Y; Takeuchi S; Tashiro Y; Kanzaki T; Kanekura T
    Bone Marrow Transplant; 2008 Jun; 41(12):1029-35. PubMed ID: 18332910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
    Shiratori S; Yasumoto A; Tanaka J; Shigematsu A; Yamamoto S; Nishio M; Hashino S; Morita R; Takahata M; Onozawa M; Kahata K; Kondo T; Ota S; Wakasa K; Sugita J; Koike T; Asaka M; Kasai M; Imamura M
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):817-23. PubMed ID: 18541202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.
    Sakamoto H; Itonaga H; Sawayama Y; Furumoto T; Fujioka M; Chiwata M; Toriyama E; Kasai S; Nakashima J; Horai M; Kato T; Sato S; Ando K; Taguchi J; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Miyazaki Y
    Hematol Oncol; 2020 Apr; 38(2):162-170. PubMed ID: 31922287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristic patterns of relapse after allogeneic hematopoietic SCT for adult T-cell leukemia-lymphoma: a comparative study of recurrent lesions after transplantation and chemotherapy by the Nagasaki Transplant Group.
    Itonaga H; Sawayama Y; Taguchi J; Honda S; Taniguchi H; Makiyama J; Matsuo E; Sato S; Ando K; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Fukushima T; Miyazaki Y
    Bone Marrow Transplant; 2015 Apr; 50(4):585-91. PubMed ID: 25621801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation.
    Kamimura T; Miyamoto T; Kawano N; Numata A; Ito Y; Chong Y; Nagafuji K; Teshima T; Hayashi S; Akashi K
    Int J Hematol; 2012 Jun; 95(6):725-30. PubMed ID: 22481502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of allogeneic hematopoietic cell transplantation in patients with adult T-cell leukemia.
    Kamiunten A; Sekine M; Kameda T; Akizuki K; Tahira Y; Shide K; Shimoda H; Kato K; Hidaka T; Kubuki Y; Shimoda K
    Hematol Oncol; 2018 Oct; 36(4):651-655. PubMed ID: 30117169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
    Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
    Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct clinical features of infectious complications in adult T cell leukemia/lymphoma patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis in the Nagasaki transplant group.
    Itonaga H; Taguchi J; Fukushima T; Tsushima H; Sato S; Ando K; Sawayama Y; Matsuo E; Yamasaki R; Onimaru Y; Imanishi D; Imaizumi Y; Yoshida S; Hata T; Moriuchi Y; Honda S; Miyazaki Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):607-15. PubMed ID: 23333533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
    Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.
    Utsunomiya A; Miyazaki Y; Takatsuka Y; Hanada S; Uozumi K; Yashiki S; Tara M; Kawano F; Saburi Y; Kikuchi H; Hara M; Sao H; Morishima Y; Kodera Y; Sonoda S; Tomonaga M
    Bone Marrow Transplant; 2001 Jan; 27(1):15-20. PubMed ID: 11244433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation.
    IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K
    Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
    Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of a Humanized CCR4 Antibody (Mogamulizumab) on Patients with Aggressive-Type Adult T-Cell Leukemia-Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
    Kawano N; Kuriyama T; Yoshida S; Kawano S; Yamano Y; Marutsuka K; Minato S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Kikuchi I
    J Clin Exp Hematop; 2017; 56(3):135-144. PubMed ID: 28331127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.